Stable ready to use cyclophosphamide liquid formulations

1. A stable liquid parenteral formulation of cyclophosphamide comprising

i) cyclophosphamide in a concentration of about 12% to about 23% based on total formulation weight;

ii) an ethanol content of about 70% to about 75% based on total formulation weight;

iii) both polyethylene glycol and propylene glycol, wherein a polyethylene glycol to propylene glycol mass ratio is between approximately 1.0:1.0 to approximately 2.0:1.0; and

iv) about 3.4% to about 8.8% based on total formulation weight of polyethylene glycol

v) about 3.4% to about 4.4% based on total formulation weight of propylene glycol

vi) wherein, after storage for 7 days at 40° C./75% RH, decomposition to form any of the following impurities is less than 0.5%:

a) bis(2-chloroethyl)amine hydrochloride;

b) 3-(2-chloroethyl)-2-oxo-2-hydroxy-1,3,6,2-oxadiazaphosphonane; and

c) 3-[2-(2-chloroethylamino)ethyl amino] propyl dihydrogen phosphate dihydrochloride.

2. The formulation of claim 1 , further comprising an antioxidant.

3. The formulation of claim 2 , wherein the antioxidant is monothioglycerol at concentration of about 0.01% to about 0.02% by total formulation weight.

4. A stable liquid parenteral formulation of cyclophosphamide comprising

i. cyclophosphamide in a concentration of about 23% based on total formulation weight

ii. an ethanol content of about 70% based on total formulation weight;

iii. both polyethylene glycol and propylene glycol, wherein a polyethylene glycol to propylene glycol mass ratio is about 1.0:1.0; and

iv. about 3.4% to about 8.8% based on total formulation weight of polyethylene glycol

v. about 3.4% to about 4.4% based on total formulation weight of propylene glycol, and

vi. about 0.02% based on total formulation weight of monothioglycerol.